Loading clinical trials...
Loading clinical trials...
This study will assess the efficacy and safety of MBP8298 compared to placebo in subjects with Secondary Progressive Multiple Sclerosis (SPMS)
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
BioMS Technology Corp.
NCT06276634 · Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting, and more
NCT06138132 · Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, and more
NCT06390930 · Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, and more
NCT06413602 · Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, and more
NCT04918225 · Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions